Five things for pharma marketers to know: Tuesday, August 4, 2020
Group petitions FDA to ban music in drug ads; GSK, Sanofi under investigation over heartburn carcinogens; Eli Lilly begins COVID-19 study in nursing homes.
Vaccines
Five things for pharma marketers to know: Monday, August 3, 2020
U.S. to pay $2.1 billion for Sanofi and GSK vaccines; COVID-19 clinical trials are not diverse; Merck to begin late-stage studies of its coronavirus treatment in September.
Never lose sight that good healthcare is a fundamental human right
The pandemic has exposed fundamental flaws in how we deliver healthcare, and the inequities are no longer tolerable. We must be the agents of change.
Five things for pharma marketers to know: Friday, July 31, 2020
Young people and long-term COVID-19 symptoms; Juul files application to sell products; FDA: Vaccine can be approved if 50% effective.
Five things for pharma marketers to know: Thursday, July 30, 2020
GSK begins trials of cancer drug found through 23andMe partnership; Roche arthritis drug fails COVID-19 trial; U.S. coronavirus deaths surpass 150,000.
Coronavirus Briefing: Vaccine optimism, GOP’s stimulus and MLB in crisis
This week’s Haymarket Media Coronavirus Briefing is 1,202 words and will take you 6 minutes to read.
Five things for pharma marketers to know: Wednesday, July 29, 2020
Advocates call on Facebook to control vaccine misinformation; Democratic lawmakers to investigate government’s role in developing remdesivir; Pfizer CEO criticizes Trump drug price orders.
Five things for pharma marketers to know: Tuesday, July 28, 2020
Experts stress importance of education about coronavirus vaccines; Vaccine alliance says $40 should be maximum cost of vaccine; Moderna begins phase 3 trial of its vaccine.
Five things for pharma marketers to know: Friday, July 24, 2020
U.S. sets benchmark for future COVID-19 vaccine prices; Researchers study wearables’ ability to detect COVID-19; Hims & Hers expands further into mental health care.
‘Next remdesivir’ should cost below $1,000: patient poll
Ninety percent of patients said the price Gilead is charging for remdesivir is not affordable, and nearly three-quarters said that the next COVID-19 treatment or vaccine should cost no more than $999.
